OHE at ISPOR 2019

Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019 conference in New Orleans, 18-22 May.

Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019 conference in New Orleans, 18-22 May.

Graham Cookson, Lotte Steuten, and Adrian Towse will all be attending the conference and contributing to the programme.

Short course: Risk Sharing / Performance-based Arrangements for Drugs and Other Medical Products

With Louis Garrison and Josh Carlson, Adrian will present at this intermediate level short course on ‘pay-for-performance’ and ‘risk-sharing’ arrangements. The presenters will discuss theory and practice in this context, including incentives and barriers, using several examples of performance-based schemes from Europe, the United States, and Australia.

Forum: ISPOR Open-source Models Special Interest Group: Lies, Damned Lies and Cost-effectiveness

In this forum discussion, moderated by Renée Arnold, Lotte will discuss some of the potential benefits of using open source decision models in health technology assessment. The forum is led by the founding members of a new ISPOR Special Interest Group.

Issue panel: The Clinical and Economic Value of Genetic Sequencing in Cancer Care: Are Next Generation Sequencing(Ngs)-based Tests Clinically Useful and Cost Effective in Real World Settings? What Is Necessary to Fully Realize Their Value?

Lotte will moderate this issue panel on next generation sequencing, providing an overview of clinical and economic evidence in the context of advanced non-small cell lung cancer. The panellists will debate the value of sequencing in cancer diagnosis, considering the role of payers and providers, and the implications of current evidence for practice and policy.

Issue panel: MCDA or Weighted CEA Based on the QALY? Which is the Future for HTA Decision Making?

Adrian will join this panel, moderated by Nancy Devlin, to present the argument in favour of using weighted cost-effectiveness analysis built around the use of quality-adjusted life years.

Issue panel: Real Option Value for Drugs: Is it Really an Option?

As moderator of this issue panel, Adrian will set out possible payer concerns about incorporating real option value into decision making. These include the potential for double counting, whether the uncertainty around estimation is being handled correctly, evidence on patient preferences, and whether prices already exceed value.